Display options
Share it on

Ann Clin Microbiol Antimicrob. 2003 Mar 07;2:5. doi: 10.1186/1476-0711-2-5.

Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital.

Annals of clinical microbiology and antimicrobials

Ugur Gonlugur, Mustafa Zahir Bakici, Levent Ozdemir, Ibrahim Akkurt, Serhat Icagasioglu, Fusun Gultekin

Affiliations

  1. Department of Chest Diseases, Cumhuriyet University Medical School, Sivas, Turkey. [email protected]

PMID: 12665428 PMCID: PMC152644 DOI: 10.1186/1476-0711-2-5

Abstract

BACKGROUND: Lower respiratory tract infections due to Pseudomonas aeruginosa have a high mortality rate. Antibacterial activity of various antibiotics against P. aeruginosa isolated from each hospital depends on the variety or amount of antibiotics used in each hospital.

METHOD: A total of 249 respiratory isolates of Pseudomonas aeruginosa in Sivas (Turkey) were included between January-1999 and January-2002. Isolates were tested against 14 different antibiotics by a disc diffusion method or standardized microdilution technique.

RESULTS: Organisms were cultured from the following specimens: sputum (31.3%), transtracheal/endotracheal aspirates (37.8%), and bronchial lavage (30.9%). Isolates in bronchial lavage were highly susceptible to cefoperazone and aminoglycosides. Resistance to ampicillin/sulbactam was 98.8%, ticarcillin 40.1%, ticarcillin/clavulanic acid 11.2%, piperacillin 21.8%, aztreonam 66.6%, cefotaxim 75.4%, ceftriaxone 84.2%, cefoperazone 39.0%, ceftazidime 50.8%, gentamicin 57.5%, tobramycin 58.4%, amikacin 25.4%, ciprofloxacin 16.1%, and imipenem/cilastatin 21.6%. The term multidrug-resistant P. aeruginosa covered resistance to imipenem, ciprofloxacin, ceftazidime, gentamicin, and piperacillin. 1.2% of isolates were multidrug-resistant.

CONCLUSIONS: These findings suggest that amikacin resistance increases progressively in Turkey. Piperacillin and ticarcillin/clavulanate were the most active agents against both imipenem- and ciprofloxacin-resistant isolates in our region.

References

  1. Am J Med. 1986 Jun 30;80(6B):76-81 - PubMed
  2. Scand J Infect Dis. 1988;20(2):199-203 - PubMed
  3. Infect Control Hosp Epidemiol. 1992 Jan;13(1):10-4 - PubMed
  4. J Antimicrob Chemother. 1996 Feb;37(2):295-301 - PubMed
  5. Semin Respir Infect. 2000 Dec;15(4):287-98 - PubMed
  6. J Antimicrob Chemother. 1998 Feb;41(2):307-10 - PubMed
  7. Antimicrob Agents Chemother. 1999 Apr;43(4):981-2 - PubMed
  8. Chest. 2001 Feb;119(2 Suppl):397S-404S - PubMed
  9. Diagn Microbiol Infect Dis. 1998 Jan;30(1):53-9 - PubMed

Publication Types